Allarity Therapeutics Launches Phase 2 Trial for Stenoparib in Advanced Ovarian Cancer
Boston-based Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced on February 24, 2025, that it is initiating a Phase 2 protocol for its experimental drug stenoparib. The new trial is aimed at advancing the candidate toward U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced ovarian cancer. According to the company’s Form […]
Boston-based Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced on February 24, 2025, that it is initiating a Phase 2 protocol for its experimental drug stenoparib. The new trial is aimed at advancing the candidate toward U.S. Food and Drug Administration (FDA) approval for the treatment of patients with advanced ovarian cancer. According to the company’s Form […]
